The diffusion of germ theory in the 19th Century Essay

The diffusion of germ theory in the 19th Century - Essay Example But Germ Theory proposed a amazing statement that the interactions with microorganisms would help us to get rid of certain diseases. â€Å"Germ Theory was developed in a social, cultural, and economic milieu increasingly centered on the values of mass production, mass consumption, standardization, and efficiency, all of which were compatible with Germ Theory science and popularization.† (Historical views of diseases and epidemics: Germ Theory, 2010). The important microbiologists in the history are Ignaz, Louis Pasteur, Robert Koch, Dmitri and Alexander Fleming. This outline needs to consider that Germ theory can be defined by way of taking three statements together and they are â€Å"Germ theory states that a disease causing microorganism should be present in animals infected by disease and not in health animals. Germ theory states that a disease causing microorganism should be present in healthy animals and not in infected animals. Germ theory states that a disease causing microorganism should be destroyed. Germ theory states that a disease causing microorganism cannot be destroyed.† (Besty 2005, p.20). There is a historical significance in developing the Germ theory. The entire world was affected by Black Death, plague and leprosy. There was no knowledge about the cause of the diseases. This kind of miseries in life make scientists think about cause of the disease and it resulted in the discovery of germ theory. With the invention of microscope the scientists started to focus on the minute part of a thing. So also the physicians began to conduct researches to discover the root cause of the disease. Looking through microscope the physicians identified the smallest microorganisms which is the cause of certain diseases. The life of the people became very difficult with the sporadic nature of various diseases. Small pox, leprosy, tuberculosis, cholera, plague

Acquiring Personal Freedom Essay -- Narrative Memoir Essays

Acquiring Personal Freedom On a cold January day, a performance broke all barriers. The crowd erupted as the curtains opened to reveal the silhouette of a rock legend. The music initiated moves that seemed to defy explanation. Long, sensuous legs captured the audience as they moved with lightning speed while voluptuous red lips seemed to pour lyrics like a fountain. Some people were in shock about who was performing, while some mystified by how the artist seemed to control the stage. The singer was creating questions with every gyration during the unstoppable performance. No one, including me, could believe what was happening on stage. How someone’s attitude can change over a small amount of time. When I entered high school, I was very self-conscience about what I did and how I acted. This mental approach really dampened my creative side and it kept me from doing a lot of things I find fun now. By the middle of my sophomore year, I was ready to do something that would stir things up a bit and get the big wheels turning. Winterfest was only a week away and I, along with the rest of the school, was ready for a little break from the monotonous everyday routine. There was a competition scheduled for Thursday which was between different â€Å"air guitar† performances. I had been to a concert earlier in the year and saw Tina Turner perform one of her most famous songs, â€Å"Proud Mary.† To my mind, the idea of dressing like Tina Turner and performing on stage was absurd. I thought about it for a few days and decided that this could be something that might break the self-conscience chains holding my spirit down. I knew it would be hard and some people might think it a little overboard, but there was only one way to fin... ...ual attire rather than the leather mini-skirt. A glint in my eye seemed to light the way out of the dim-lit bathroom. Today, when confronted with a challenge, I just look back at this experience to help me through it. After I performed in front of the school in a skirt and high heels, some things seem minuscule. By overpowering my self-conscience feelings, I am now able to do things without caring how people might view me. I have noticed that my newly gained social confidence helps me through everything from interviews to relationships. On a cold January day, a performance broke all barriers blocking me from my goals. I did something I had never done and discovered that what others thought would not control my life any longer. On that day, my spirit escaped the bounding chains and set my big wheels in motion with no sign of stopping anytime soon.

Eli Lilly: Developing Cymbalta

Eli Lilly and company is a pharmaceutical company that was established in 1876 by Colonel Eli Lilly, who had served in the union army during the Civil War. One of the products the company developed includes the antidepressant drug Prozac, which has been a legendary product for the company and has generated billions of dollars since its launch. As Prozac’s patent expiration date approached, thereby allowing the sale of generic versions in the U. S. , the company decided to pursue a product to replace Prozac, named Cymbalta. John Kaiser, the marketing director at Eli Lilly and member of a cross-functional R&D team, new anti-depressant team (NAT), has been tasked to lead this effort. Kaiser prepared a presentation about the potential successor, Cymbalta, and convened a meeting with the NAT members to discuss its future potential. The goal of the meeting was to thoroughly analyze and discuss the pros and cons about Cymbalta’s development and strategic opportunities based on the different options of use. This paper will identify the strategic issues and problems the NAT faced in developing the new product. The paper will then analyze and evaluate the industry and market behavior by using a SWOT analysis. Finally, this paper will offer a set of recommendations based on the surrounding circumstances and options available to the Eli Lilly team. Identification of the strategic issues and problems: Eli Lilly and company’s NAT members began the process of searching for a successful replacement to Prozac by looking into the strategic choices, possibilities, and successful launch of a replacement shortly after the expiration of Prozac’s patent. Cymbalta was considered as a viable successor to Prozac because it seemed a) to be as good as or better than existing antidepressants, b) to show no signs of safety precautions or toxicity issues, c) to meet previous unmet patient needs, and d) to show promising signs of development as a product to also treat pain, especially if it did not cause special side effects. However, when Lilly developed Cymbalta back in the early 1990’s, for the major depressive disorder (MDD) market, the product failed to show satisfactory levels of efficacy for treating MDD in phase 2 trials in 1993. Additionally, Lilly had so little experience in the therapeutic area. Moreover, there were variances in the opinions of Neurologists and Psychiatrists related to the symptoms of pain, such as chronic back pain or recurring headache tied to depression. Those variances could peril the decision making process from the top management. Also, since there were no clear guidelines from the Food and Drug Administration (FDA), for the development of pain indications associated to depression, the likelihood of FDA approval was very slim. Kaiser and the team also encountered several constraints. The team had to decide how to prioritize the clinical trials for Cymbalta within the range of $25 to $50 million and a time frame of 15 to 18 months to design, enroll patients for trial, and then analyze and document results for the clinical trial. Each study was a major task for the NAT members and the team had the opportunity to submit only one objective to the FDA for marketing approval. On the other hand, since Cymbalta had been tested with twice daily dosages of 20 mg, 30 mg, and 40 mg, NAT members also looked into the option of conducting a new set of clinical trials to establish once-a-day dosage of 60 mg of Cymbalta to treat Major Depressive Disorder (MDD). The new option would provide more expedient dosing for patients and would also put the product on par with the major competitors. Analysis and Evaluation: The U. S. pharmaceutical industry is complex and dynamic. It’s an industry that is characterized by high-tech research and development (R&D) expenditures and extensive regulation of its products, especially in comparison with other manufacturing sectors. The U. S. Food and Drug Administration (FDA) oversee policies that produce faster review and approval times for drugs. The agency carefully evaluates the safety of any new drug and its efficacy. Such policies result in extended periods during which companies can exclusively market their pharmaceutical products. Longer periods of market exclusivity for pharmaceuticals then increase sales revenues, and increased sales revenues in turn lead to greater profits and potentially more funding for R&D. Treatment of depression is one area that the U. S. pharmaceutical industry has heavily invested in. The total sales of U. S. antidepressants reached close to $9 billion in the year 2000. Companies such as Eli Lilly capitalized on this opportunity and became a leading force in the antidepressant market with its Prozac drug. Antidepressant product development companies invest heavily in Research and Development (R&D), and patent it. With each successful launch of a product, they enjoy its patent rights for quite a long period of time and enjoy the exclusive rights to produce and sell that product resulting in enormous profits for the company. Thus, drug companies continuously attempt to differentiate their product from competitors and bundle in such a way that is more tailored to segment of the market where they can realize higher profits. SWOT Analysis: Strengths: †¢Potential successor to a highly successful brand – Prozac from a well-established company in the pharmaceutical industry. Part of the selective serotonin reuptake inhibitors (SSRI) group of drugs, which is popular and had fewer side effects than tricyclic anti-depressant (TCA) and monoamine oxidase inhibitors (MAOI). †¢Potential to treat both depression and chronic pain, such as headache and backache caused by depression. Weaknesses: †¢Product that is not different from competitors' brands. †¢Twice-a-day dosing regimen of 20-40 mg. Threats: †¢Serious market competition from competitors' brands such as Paxils and Zoloft with same efficacy. No clear concession amongst physicians as to the nature of link between depression and pain. †¢Attempting to compare Cymbalta to existing SSRI on pain might fail to conclusively separate from competitors, thus giving rival drugs an implicit endorsement for treating pain. Opportunities: †¢Potential development of 60 mg once-a-day dosage with high efficacy. †¢The possibility of pursuing patients with fibromyalgia (severe muscle pain and chronic fatigue) and Diabetic peripheral neuropathic pain or DPNP (a painful and debilitating complication of diabetes). According to the National Studies of Health, over 40 million Americans were unable to find relief from their pain, including patients with fibromyalgia and DPNP. Pros and Cons of Plausible Alternatives: If developed successfully, Cymbalta could be a unique product that has the ability to significantly reduce and improve depression and pain. Patients with fibromyalgia and DPNP could greatly benefit from Cymbalta. The pain relief may also be great for patients who suffer from depression and chronic pain like headache and backache. The NAT’s idea of pursuing the 60 mg daily dosage is also attractive if it delivers the same efficacy of current antidepressant drugs in the market. However, all of this comes with its perils. The company has to evaluate the risks and any potential side effects that the 60 mg per day dosage may have on patients. They also have to assess the feasibility of conducting a clinical trial with a 15 to 18 months’ timeframe and a projected cost of $25 to $50 million. Additionally, they would have to convince the FDA that the new product is ready to market. Failure of any of the aforementioned obstacles could result in loss of the antidepressant market to competitors. Recommendations: Depression and chronic pain diseases, such as fibromyalgia and DPNP, have a profound effect in society at large. Studies in scientific publications have estimated that depression affects 10% to 25% of the population. The antidepressant market in the U. S. in 2000 totaled sales of approximately $9 billion. Eli Lilly has positioned itself well in this market segment. The company has enjoyed a market lead with annual sales of over $2 billion with its antidepressant drug, Prozac. Cymbalta needs to focus on maintaining and increasing that $2 billion dollar revenue Prozac has achieved over the past years, by building on the successful foundations Prozac has already established. It is important to develop an updated product that will undoubtedly outperform its competitors. Cymbalta might be a successful replacement because of its good efficacy or efficacy better than existing antidepressants, Cymbalta also has no apparent safety or toxicity issues, and its possibilities of meeting a previously unmet patient needs, exemplifies why Cymbalta has the potential to total higher record sales than even Prozac.

Anthropology As A Central Standard Of Human Studies

Anthropology is the investigation of mankind in all times and places. Anthropology contains four fields of subdisciplines: social humanities, linguistic humanities, prehistoric studies, and physical or natural humanities. In each of human sciences fields a few people improve connected humanities, which utilizes anthropological learning to take care of useful issues. Cultural anthropologists study people in term of their societies, the frequently ignorant measures by which social gathering work. Linguistic anthropology study human language and may manage the depiction of a dialect, with the historical backdrop of languages, or with how dialects are utilized as a part of specific social settings. Linguistic was my favorite category to†¦show more content†¦After the hands on work, specialists conduct research examination of unearthed remains or natural examples gathered in the field. A long ritual of considering the associations among different people, gives human sciences a h ypothetical structure to study. The study of scientific categorization, taxonomy, arranges living creatures into a progression of dynamically more comprehensive classifications on the evidence of inner and outside visual similarities. The principal framework to characterize living things was System Naturae. It was based on the foundation of similarities in body structure, body capacity, and cycle of development. This same system now takes a gander at attributions. For example, organic reactions of blood, protein structure, and the cosmetics of the hereditary material itself. Development is implied as far as four powers that influence the hereditary structures of population which include: mutation, genetic drift, gene flow, and natural selection. Alleles are altered types of a gene for a specified trait. The complete number of diverse alleles of genes offered to a population is known as a gene pool. The components of heredity, genes, are fragments of atoms of DNA, and the whole sequence groups of species. The human DNA gives the directions to the thousand of proteins that allow us to be alive and well. DNA atoms can create exact duplicates of themselves,